EUVIMEDEUVIMED entdecken
Crossref

A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non‐factor VIII related haemostasis assays

Annette Elizabeth Bowyer iD, Kieron Hickey, Steve Kitchen, Mirella Ezban iD

Haemophilia · 2023

DOI: 10.1111/hae.14884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Annette Elizabeth Bowyer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Coagulation, Sheffield Teaching Hospitals NHS FT, Sheffield, UK. Hauptthemen laut MEDLINE: Blood Coagulation, Hemophilia A. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and aims Mim8 is a next generation bispecific antibody developed for the treatment of haemophilia A (HA). Mim8 has an increased potency compared to first generation molecules. The impact on Mim8 on non‐FVIII measuring haemostasis assays was assessed in plasma containing Mim8. Methods Congenital severe HA plasma was spiked with increasing concentrations of Mim8 (0–20 μg/mL). 28 routine and specialist haemostasis assays were used to measure activities. These included tests for prothrombin time (PT), fibrinogen, thrombin, D‐dimer, anti‐Xa, heparin induced thrombocytopenia (HIT), clotting factors II–XII, factor XIII, von Willebrand factor (VWF), thrombophilia and DRVVT. Results and conclusions Less than 10 % difference was calculated between plasma without Mim8 and plasma spiked to 15 μg/mL Mim8 in all assays except thrombin time (−10.5%), APTT‐based factor IX, XI and XII, Werfen VWF:RCo (10.6%) and Siemens LA1 (−26.4%) and LA2 (−16.9%). At the expected therapeutic steady state levels of Mim8 (5–8 μg/mL), less than 10% difference was calculated for thrombin time and Werfen VWF:RCo. APTT‐based assays of FIX, XI and XII are significantly elevated in the presence of Mim8 and should not be performed. A chromogenic FIX assay could be used to accurately measure FIX activity in the presence of Mim8. There was some interference in the DRVVT method we used so local assessment of other DRVVT methods is advised. Differences in all other tests would not be predicted to affect patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood CoagulationHemophilia AHumansvon Willebrand FactorHemostasisBlood Coagulation TestsProthrombin Time

Stichwörter der Autor:innen

Mim8bispecific antibodychromogenichaemophiliaone-stage

Substanzen

von Willebrand Factor

Autor:innen und Institutionen

  • Department of Coagulation, Sheffield Teaching Hospitals NHS FT, Sheffield, UK.
  • Rare Disease Research, Global Drug Discovery, Novo Nordisk, Måløv, Denmark.

ORCID-Profile: Annette Elizabeth Bowyer, Mirella Ezban

Förderung

  • Novo Nordisk

Zitieren

APA

Bowyer, A. E., Hickey, K., Kitchen, S., & Ezban, M. (2023). A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non‐factor VIII related haemostasis assays. Haemophilia. https://doi.org/10.1111/hae.14884

Vancouver

Bowyer AE, Hickey K, Kitchen S, Ezban M. A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non‐factor VIII related haemostasis assays. Haemophilia. 2023. doi:10.1111/hae.14884

BibTeX
@article{Bowyer2023,
  author = {Bowyer, Annette Elizabeth and Hickey, Kieron and Kitchen, Steve and Ezban, Mirella},
  title = {A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non‐factor VIII related haemostasis assays},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14884}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche